OTLK

Outlook Therapeutics (OTLK)

About Outlook Therapeutics (OTLK)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Details

Daily high

$1.77

Daily low

$1.66

Price at open

$1.73

52 Week High

$9.25

52 Week Low

$0.87

Market cap

57.1M

Dividend yield

0.00%

Volume

621,595

Avg. volume

398,636

P/E ratio

-1.22

Outlook Therapeutics News